Literature DB >> 16896043

The prevalence of CDKN2A germ-line mutations and relative risk for cutaneous malignant melanoma: an international population-based study.

Marianne Berwick1, Irene Orlow, Amanda J Hummer, Bruce K Armstrong, Anne Kricker, Loraine D Marrett, Robert C Millikan, Stephen B Gruber, Hoda Anton-Culver, Roberto Zanetti, Richard P Gallagher, Terence Dwyer, Timothy R Rebbeck, Peter A Kanetsky, Klaus Busam, Lynn From, Urvi Mujumdar, Homer Wilcox, Colin B Begg.   

Abstract

Germ-line mutations of CDKN2A have been identified as strong risk factors for melanoma in studies of multiple-case families. However, an assessment of their relative risk for melanoma in the general population has been difficult because they occur infrequently. We addressed this issue using a novel population-based case-control study design in which "cases" have incident second- or higher-order melanomas [multiple primary melanoma (MPM)] and "controls" have incident first primary melanoma [single primary melanoma (SPM)]. Participants were ascertained from nine geographic regions in Australia, Canada, Italy, and United States. In the 1,189 MPM cases and 2,424 SPM controls who were eligible and available for analysis, the relative risk of a subsequent melanoma among patients with functional mutations who have an existing diagnosis of melanoma, after adjustments for age, sex, center, and known phenotypic risk factors, is estimated to be 4.3 (95% confidence interval, 2.3-7.7). The odds ratio varied significantly depending on the type of mutation involved. The results suggest that the relative risk of mutation carriers in the population may be lower than currently believed and that different mutations on the CDKN2A gene may confer substantially different risks of melanoma.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16896043     DOI: 10.1158/1055-9965.EPI-06-0270

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.254


  44 in total

1.  Does MC1R genotype convey information about melanoma risk beyond risk phenotypes?

Authors:  Peter A Kanetsky; Saarene Panossian; David E Elder; DuPont Guerry; Michael E Ming; Lynn Schuchter; Timothy R Rebbeck
Journal:  Cancer       Date:  2010-05-15       Impact factor: 6.860

2.  Risk of non-melanoma cancers in first-degree relatives of CDKN2A mutation carriers.

Authors:  Bhramar Mukherjee; John Oliver Delancey; Leon Raskin; Jessica Everett; Joanne Jeter; Colin B Begg; Irene Orlow; Marianne Berwick; Bruce K Armstrong; Anne Kricker; Loraine D Marrett; Robert C Millikan; Hoda Anton Culver; Stefano Rosso; Roberto Zanetti; Peter A Kanetsky; Lynn From; Stephen B Gruber
Journal:  J Natl Cancer Inst       Date:  2012-04-24       Impact factor: 13.506

3.  Characterization of melanoma susceptibility genes in high-risk patients from Central Italy.

Authors:  Cristina Pellegrini; Maria Giovanna Maturo; Claudia Martorelli; Mariano Suppa; Ambra Antonini; Dimitra Kostaki; Lucilla Verna; Maria Teresa Landi; Ketty Peris; Maria Concetta Fargnoli
Journal:  Melanoma Res       Date:  2017-06       Impact factor: 3.599

4.  The use of hierarchical models for estimating relative risks of individual genetic variants: an application to a study of melanoma.

Authors:  Marinela Capanu; Irene Orlow; Marianne Berwick; Amanda J Hummer; Duncan C Thomas; Colin B Begg
Journal:  Stat Med       Date:  2008-05-20       Impact factor: 2.373

5.  CDKN2A Germline Rare Coding Variants and Risk of Pancreatic Cancer in Minority Populations.

Authors:  Robert R McWilliams; Eric D Wieben; Kari G Chaffee; Samuel O Antwi; Leon Raskin; Olufunmilayo I Olopade; Donghui Li; W Edward Highsmith; Gerardo Colon-Otero; Lauren G Khanna; Jennifer B Permuth; Janet E Olson; Harold Frucht; Jeanine Genkinger; Wei Zheng; William J Blot; Lang Wu; Luciana L Almada; Martin E Fernandez-Zapico; Hugues Sicotte; Katrina S Pedersen; Gloria M Petersen
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2018-07-23       Impact factor: 4.254

6.  Occupational sun exposure and risk of melanoma according to anatomical site.

Authors:  Kylie Vuong; Kevin McGeechan; Bruce K Armstrong; Anne E Cust
Journal:  Int J Cancer       Date:  2013-11-29       Impact factor: 7.396

7.  Benefits of oral Polypodium Leucotomos extract in MM high-risk patients.

Authors:  P Aguilera; C Carrera; J A Puig-Butille; C Badenas; M Lecha; S González; J Malvehy; S Puig
Journal:  J Eur Acad Dermatol Venereol       Date:  2012-07-31       Impact factor: 6.166

Review 8.  Aetiology, genetics and prevention of secondary neoplasms in adult cancer survivors.

Authors:  Lois B Travis; Wendy Demark Wahnefried; James M Allan; Marie E Wood; Andrea K Ng
Journal:  Nat Rev Clin Oncol       Date:  2013-03-26       Impact factor: 66.675

9.  Chromosome 9p21 SNPs Associated with Multiple Disease Phenotypes Correlate with ANRIL Expression.

Authors:  Michael S Cunnington; Mauro Santibanez Koref; Bongani M Mayosi; John Burn; Bernard Keavney
Journal:  PLoS Genet       Date:  2010-04-08       Impact factor: 5.917

10.  Evaluation of the clonal origin of multiple primary melanomas using molecular profiling.

Authors:  Irene Orlow; Diana V Tommasi; Bradley Bloom; Irina Ostrovnaya; Javier Cotignola; Urvi Mujumdar; Klaus J Busam; Achim A Jungbluth; Richard A Scolyer; John F Thompson; Bruce K Armstrong; Marianne Berwick; Nancy E Thomas; Colin B Begg
Journal:  J Invest Dermatol       Date:  2009-03-12       Impact factor: 8.551

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.